Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone to High-Dose Treatment With ASCT in the Initial Management of Myeloma in Patients up to 65 Years of Age

Next Previous
Trial Profile

Randomized Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone to High-Dose Treatment With ASCT in the Initial Management of Myeloma in Patients up to 65 Years of Age

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms IFM/DFCI 2009

    • Most Recent Events

    • 12 May 2022 Results of an analysis of a sub-study of IFM/DFCI 2009 cohort assessed the venous thromboembolism incidence, risk factors and risk score published in the Journal of Thrombosis and Haemostasis
    • 17 Jun 2021 Results of meta-analysis of randomized controlled trials (IFM 2009, EMN02/HOVON 95, RV-MM-EMN-441, RV-MM-PI-209 and FORTE), assessing association of HDT-AHCT with PFS in newly diagnosed high-risk myeloma, with overall survival being the secondary objective, presented at the 26th Congress of the European Haematology Association.
    • 14 Jan 2021 Results of a pooled analysis (of data extracted from NCT01712789, NCT02773030, NCT01421524, NCT01191060 studies and Myeloma Genome Project) assessing multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma published in the Blood
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top